FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated by the Sponsor.

Conditions

Acute Myeloid Leukemia
AML, Adult
Multiple Myeloma
Myeloma

Interventions

DRUG: FT538
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Daratumumab
DRUG: Elotuzumab

Sponsor

Fate Therapeutics